Status:
COMPLETED
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Lead Sponsor:
Cerenis Therapeutics, SA
Conditions:
Homozygous Familial Hypercholesterolemia
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The available medications used to treat HoFH are targeted at reducing circulating levels of total and LDL-cholesterol. These measures can retard the progression of cardiovascular disease, however, the...
Eligibility Criteria
Inclusion
- Male or female subject 12 years or older
- Subject presents with Homozygous FH
Exclusion
- Weight \>100 kg
- Subjects with significant health problems in the recent past including blood disorders, cancer, or digestive problems
- Female subjects of child-bearing potential
- Known major hematologic, renal , hepatic, metabolic, gastrointestinal or endocrine dysfunction
- Contraindication to MRI scanning that would preclude the use of contrast-enhanced 3TMRI
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01412034
Start Date
November 1 2011
End Date
August 1 2014
Last Update
August 18 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Facility
Hartford, Connecticut, United States, 06102
2
Clinical Research Facility
North Massapequa, New York, United States, 11758
3
Clinical Research Facility
Chicoutimi, Quebec, Canada, G7H 7P2
4
Clinical Research Facility
Québec, Quebec, Canada, G1V4M6